HC Wainwright Reiterates Buy Rating for ACHV
HC Wainwright maintains a buy rating on ACHV with a $12 price target, a 126.84% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on ACHV, maintaining a price target of $12.
- HC Wainwright's $12 price target implies 126.84% upside from Achieve Life Sciences, Inc.'s ($ACHV) current $5.29 share price.
- ACHV shares traded at $5.29 on Monday, reflecting ongoing interest from analysts.
- Peer funds like Vanguard Capital Management opened new positions in ACHV, showing varied institutional activity.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reaffirmed its buy rating on ACHV, setting a price target of $12 as of June 22, 2026. This reiteration comes as part of their ongoing analysis of the company.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. reiterated its buy rating for ACHV with a price target of $12. Earlier, on April 21, 2026, Canaccord Genuity initiated coverage with a buy rating and a $13 target. These ratings underscore the continued interest in ACHV from analysts.
Other Institutional Activity in ACHV
Vanguard Capital Management LLC opened a new position in ACHV, acquiring 2,204,714 shares valued at approximately $6.48 million. Meanwhile, Millennium Management LLC reduced its holdings by 281,778 shares, now holding 1,077,338 shares worth about $3.17 million. Other funds like Franklin Resources Inc. and Simplify Asset Management Inc. maintained their positions without any changes.
Insider Buying and Selling at Achieve Life Sciences, Inc.
Recent insider activity at ACHV includes significant buying by key personnel. On May 29, 2026, insiders Waldman Reid Alexander and Jeffrey Farrow each purchased 47,250 shares. Earlier, on April 18, 2026, CEO and President Andrew Goldberg made multiple purchases, including 11,706,270 shares.
Bottom Line
HC Wainwright's reiterated buy rating and $12 price target reflect a positive outlook for ACHV. With varied institutional activity and insider buying, the company remains a focal point for investors. Remember, 13F filings and analyst ratings are backward-looking and may not represent the most current positions or sentiments.
Get Achieve Life Sciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ACHV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.